PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives

European Journal of Medicinal Chemistry

Volumn 109, Issue , 2016, Pages 314-341

  Asati, Vivek ^a   Mahapatra, Debarshi Kar ^a   Bharti, Sanjay Kumar ^a  

^a GURU GHASIDAS UNIVERSITY   (India)

Author keywords

Cancer; Inhibitors; PI3K; Ras; SAR; Signaling pathways

Indexed keywords

1,2,4 TRIAZOLE DERIVATIVE; ANTINEOPLASTIC AGENT; BENZOXEPIN DERIVATIVE; INDOLE DERIVATIVE; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE B; PYRIMIDINE DERIVATIVE; PYRROLIDINE DERIVATIVE; RAF PROTEIN; RAS PROTEIN; TRIAZOLE DERIVATIVE; ENZYME INHIBITOR; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

CANCER THERAPY; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL (TOPIC); HUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; METABOLISM; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DISCOVERY; ENZYME INHIBITORS; HUMANS; MAP KINASE SIGNALING SYSTEM; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RAF KINASES; RAS PROTEINS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84955287687     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2016.01.012     Document Type: Short Survey

References (156)

1. Cancer Facts & Figures. American Cancer Society. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc (accessed 02.09.14).
2. Globocan. http://globocan.iarc.fr/Pages/fact-sheets-cancer.aspx (accessed 29.11.14).
3. R.A. Smith, V. Cokkinides, D. Brooks, D. Saslow, and O.W. Brawley Cancer screening in the United States, 2010: a review of current American Cancer Society guidelines and issues in cancer screening, CA Cancer J. Clin. 60 2 2010 99 119
4. J.C. Reed Apoptosis-based therapies Nat. Rev. Drug Discov. 1 2002 111 121
5. J.C. Reed, and M. Pellecchia Apoptosis-based therapies for hematologic malignancies Blood 106 2005 408 418
6. Q.P. Peterson, D.C. Hsu, D.R. Goode, C.J. Novotny, R.K. Totten, and P.J. Hergenrother Procaspase-3 activation as an anti-cancer strategy: structure-activity relationship of procaspase-activating compound 1 (PAC-1) and its cellular colocalization with caspase-3 J. Med. Chem. 52 2009 5721 5731
7. S.X. Cai, B. Nguyen, S. Jia, J. Herich, J. Guastella, S. Reddy, B. Tseng, J. Drewe, and S. Kasibhatla Discovery of substituted N-phenyl nicotinamides as potent inducers of apoptosis using a cell- and caspase-based high throughput screening assay J. Med. Chem. 46 2003 2474 2481
8. P. Cohen Protein kinases the major drug targets of the twenty-first century? Nat. Rev. Drug Discov. 1 2002 309 315
9. C. Porta, and R.A. Figlin Phosphatidylinositol-3-kinase/Akt signaling pathway and kidney cancer and the therapeutic potential of phosphatidylinositol-3- kinase/Akt inhibitors J. Urol. 182 2009 2569 2577
10. N. Gao, Z. Zhang, B.H. Jiang, and X. Shia Role of PI3K/Akt/mTOR signaling in the cell cycle progression of human prostate cancer Biochem. Biophys. Res. Commun. 310 2003 1124 1132
11. J.A. Engelman Targeting PI3K signalling in cancer: opportunities, challenges and limitations Nat. Rev. 9 2009 550 562
12. M. Kobayashi, S. Nagata, and T. Iwasaki Dedifferentiation of adenocarcinomas by activation of phosphatidylinositol 3-kinase Proc. Natl. Acad. Sci. 96 1999 4874 4879
13. J. Li, C. Yen, and D. Liaw PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer Science 275 1997 1943 1947
14. I. Sansal, and W.R. Sellers The biology and clinical relevance of the PTEN tumor suppressor pathway J. Clin. Oncol. 22 2004 2954 2963
15. F. Chang, J.T. Lee, and P.M. Navolanic Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy Leukemia 17 2003 590 603
16. J.A. Diehl, M. Cheng, M.F. Roussel, and C.J. Sherr Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization Genes Dev. 12 1998 3499 3511
17. E. Ruoslahti Fibronectin and its integrin receptors in cancer Adv. Cancer Res. 76 1999 1 20
18. S.A. Edwards, T. Darland, and R. Sosnowski The transcription factor, Egr-1, is rapidly modulated in response to retinoic acid in P19 embryonal carcinoma cells Dev. Biol. 148 1991 165 173
19. V.P. Sukhatme, X.M. Cao, and L.C. Chang A zinc finger-encoding gene coregulated with c-fos during growth and differentiation, and after cellular depolarization Cell 53 1998 37 43
20. F. Meric-Bernstam, A. Akcakanat, H. Chen, K.A. Do, T. Sangai, F. Adkins, A.M. Gonzalez-Angulo, A. Rashid, K. Crosby, M. Dong, A.T. Phan, R.A. Wolff, S. Gupta, G.B. Mills, and J. Yao PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors Clin. Cancer Res. 18 2012 1777 1789
21. I. Vivanco, and C.L. Sawyers The phosphatidylinositol 3-kinase-Akt pathway in human cancer Nat. Rev. Cancer 2 2002 489 501
22. D.A. Guertin, and D.M. Sabatini Defining the role of mTOR in cancer Cancer Cell. 12 2007 9 22
23. B. Hassan, A. Akcakanat, A.M. Holder, and F. Meric-Bernstam Targeting the PI3K/Akt/mTOR signaling pathway Surg. Oncol. Clin. N. Am. 22 4 2013 641 664
24. A.T. Sasaki, and R.A. Firtel Finding the way: directional sensing and cell polarization through Ras signaling Novartis Found. Symp. 269 2005 73 87
25. D.L. Stirewalt, K.J. Kopecky, S. Meshinchi, F.R. Appelbaum, M.L. Slovak, and C.L. William FLT3, Ras and TP53 mutations in elderly patients with acute myloid leukemia Blood 97 2001 3589
26. P.J. Roberts, and C.J. Der Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer Oncogene 26 2007 3291
27. F. Chang, J.T. Lee, P.M. Navolanic, L.S. Steelman, J.G. Shelton, W.L. Blalock, R.A. Franklin, and J.A. McCubrey Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy Leukemia 17 2003 590
28. J.A. Mc Cubrey, L.S. Steelman, W.L. Chappel, S.L. Abrams, E.W.T. Wong, F. Chang, B. Lehmann, D.M. Terrian, M. Milella, A. Tafuri, F. Stivala, M. Libra, J. Basecke, E. Camilla, M.M. Alberto, and R.A. Franklin Role of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance Biochim. Biophys. Acta 1773 2007 1263 1284
29. M.O. Ripple, N. Kim, and R.J. Springett Acute mitochondrial inhibition by mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK) 1/2 inhibitors regulates proliferation Biol. Chem. 288 2013 5374
30. J. Elina, L. Niina, and P.K. Jussi Alternative dosing of dual PI3K and MEK inhibition in cancer therapy BMC Cancer 12 2012 612
31. M.C. Good, J.G. Zalatan, and W.A. Lim Scaffold proteins: hubs for controlling the flow of cellular information Science 332 2011 680 686
32. J.K. Polka, and P.A. Silver Building synthetic cellular organization Mol. Biol. Cell. 24 23 2013 3585 3587
33. E.C. Greenwald, J.M. Redden, K.L. Dodge-Kafka, and J.J. Saucerman Scaffold state switching amplifies, accelerates, and insulates protein kinase C signaling J. Biol. Chem. 289 4 2014 2353 2360
34. E.R. Levin Plasma membrane estrogen receptors Trends Endocrinol. Metab. 20 10 2009 477 482
35. M. Razandi, A. Pedram, G.L. Greene, and E.R. Levin Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ERalpha and ERbeta expressed in Chinese hamster ovary cells Mol. Endocrinol. 13 2 1999 307 319
36. Z. Liu, S. Chen, S. Boyle, Y. Zhu, A. Zhang, D.R. Piwnica-Worms, M.X.G. Ilagan, and K. Raphael The extracellular domain of notch2 increases its cell-surface abundance and ligand responsiveness during kidney development Devcel 25 6 2013 585 598
37. R. Rhoades, and D.R. Bell Medical Physiology: Principles of Clinical Medicine fourth ed. 2013 Lippincott Williams & Wilkins 287p
38. S. Swerdlow, and C.W. Distelhorstemail Bcl-2-regulated calcium signals as common mediators of both apoptosis and autophagy Devcel 12 2 2007 178 179
39. M. Jaganjac, T. Cacev, A. Cipak, S. Kapitanović, K.G. Troselj, and N. Zarković Even stressed cells are individuals: second messengers of free radicals in pathophysiology of cancer Croat. Med. J. 53 4 2012 304 309
40. J.M. Berg, J.L. Tymoczko, and L. Stryer Biochemistry fifth ed. 2002 W H Freeman New York 601
41. M. Jaganjac, T. Čačev, A. Čipak, S. Kapitanović, K.G. Trošelj, and N. Zarković Even stressed cells are individuals: second messengers of free radicals in pathophysiology of cancer Croat. Med. J. 53 4 2012 304 309
42. C.A. Lange, and D. Yee Killing the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancer Endocr. Relat. Cancer 18 4 2011 C19 C24
43. M. Laplante, and D.M. Sabatini mTOR signaling in growth control and disease Cell 149 2012 274 293
44. K.H. Khan, T.A.Y.L. Yan, and D. Cunningham Targeting the PI3K-mTOR network in cancer Chin. J. Cancer 32 5 2013 253 265
45. V. Asati, D.K. Mahapatra, and S.K. Bharti Thiazolidine-2,4-diones as multi-targeted scaffold in medicinal chemistry: potential anticancer agents Eur. J. Med. Chem. 87 2014 814 833
46. C. Porta, C. Paglino, and A. Mosca Targeting PI3K/Akt/mTOR signaling in cancer Front. Oncol. 4 2014 1 11
47. B. Vanhaesebroeck, S.J. Leevers, G. Panayotou, and M.D. Waterfield Phosphoinositide 3-kinases: a conserved family of signal transducers Trends Biochem. Sci. 22 1997 267 272
48. B.D. Cuevas, Y. Lu, M. Mao, J. Zhang, R. LaPushin, K. Siminovitch, and G.B. Mills Tyrosine phosphorylation of p85 relieves its inhibitory activity on phosphatidylinositol 3-kinase J. Biol. Chem. 276 2001 27455 27461
49. J.A. Fresno-Vara, E. Casado, J. De Castro, P. Cejas, C. Belda-Iniesta, and M. Gonzales Baron PI3K/Akt signaling pathway and cancer Cancer Treat. Rev. 30 2004 193 204
50. B. Vanhaesebroeck, and D.R. Alessi The PI3K-PDK1 connection: more than just a road to PKB Biochem. J. 346 2000 561 576
51. B. Vanhaesebroeck, and M.D. Waterfield Signaling by distinct classes of phosphoinositide 3-kinases Exp. Cell Res. 253 1999 239 254
52. L.C. Foukas, C.A. Beeton, J. Jensen, W.A. Phillips, and P.R. Shepherd Regulation of phosphoinositide 3-kinase by its intrinsic serine kinase activity in vivo Mol. Cell Biol. 24 3 2004 966 975
53. M.J. Zinda, M.A. Johnson, J.D. Paul, C. Horn, B.W. Konicek, Z.H. Lu, G. Sandusky, J.E. Thomas, B.L. Neubauer, M.T. Lai, and J.R. Graff Akt-1,-2, and-3 are expressed in both normal and tumor tissues of the lung, breast, prostate, and colon Clin. Cancer Res. 7 2001 2475 2479
54. M.P. Scheid, M. Parsons, and J.R. Woodgett Phosphoinositide-dependent phosphorylation of PDK1 regulates nuclear translocation Mol. Cell Biol. 25 6 2005 2347 2363
55. M. Andjelković, D.R. Alessi, R. Meier, A. Fernandez, N.J. Lamb, M. Frech, P. Cron, P. Cohen, J.M. Lucocq, and B.A. Hemmings Role of translocation in the activation and function of protein kinase B J. Biol. Chem. 272 1997 31515 31524
56. D.P. Brazil, J. Park, and B.A. Hemmings PKB binding proteins: getting in on the Akt Cell 111 2002 293 303
57. D.J. Powell, E. Hajduch, G. Kular, and H.S. Hundal Ceramide disables 3-phosphoinositide binding to the pleckstrin homology domain of protein kinase B (PKB)/Akt by a PKCzeta-dependent mechanism Mol. Cell Biol. 23 2003 7794 7808
58. N.M. Conus, K.M. Hannan, B.E. Cristiano, B.A. Hemmings, and R.B. Pearson Direct identification of tyrosine 474 as a regulatory phosphorylation site for the Akt protein kinase J. Biol. Chem. 277 2002 38021 38028
59. J.C. Obenauer, L.C. Cantley, and M.B. Yaffe Scansite 2.0: proteome-wide prediction of cell signaling interactions using short sequence motifs Nucleic Acids Res. 31 2003 3635 3641
60. S. Wullschleger, R. Loewith, and M.N. Hall TOR signaling in growth and metabolism Cell 124 2006 471 484
61. L. Wang, T.E. Harris, and J.C. Lawrence Regulation of proline-rich Akt substrate of 40 kDa (PRAS40) function by mammalian target of rapamycin complex 1 (mTORC1)-mediated phosphorylation J. Biol. Chem. 283 2008 15619 15627
62. E. Jacinto, V. Facchinetti, D. Liu, N. Soto, S. Wei, S.Y. Jung, Q. Huang, J. Qin, and B. Su SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity Cell 127 2006 125 137
63. Q. Yang, K. Inoki, T. Ikenoue, and K.L. Guan Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity Gene Dev. 20 2006 2820 2832
64. B.T. Navé, M. Ouwens, D.J. Withers, D.R. Alessi, and P.R. Shepherd Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and aminoacid deficiency on protein translation Biochem. J. 344 1999 427 431
65. K. Inoki, Y. Li, T. Zhu, J. Wu, and K.L. Guan TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signaling Nat. Cell Biol. 4 2002 648 657
66. B.D. Manning, A.R. Tee, M.N. Logsdon, J. Blenis, and L.C. Cantley Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-Kinase/Akt pathway Mol. Cell 10 2002 151 162
67. C.J. Potter, L.G. Pedraza, and T. Xu Akt regulates growth by directly phosphorylating Tsc2 Nat. Cell Biol. 4 2002 658 665
68. F. Meric-Bernstam, and A.M. Gonzalez-Angulo Targeting the mTOR Signaling Network for Cancer Therapy J. Clin. Oncol. 27 2009 2278 2287
69. C. Wellbrock, M. Karasarides, and R. Marais The RAF proteins take centre stage Nat. Rev. Mol. Cell Biol. 5 2004 875 885
70. B. Gay, S. Suarez, G. Caravatti, P. Furet, T. Meyer, and J. Schoepfer Selective GRB2 SH2 inhibitors as anti-Ras therapy Int. J. Cancer 83 2 1999 235 241
71. E.K. Rowinsky, J.J. Windle, and D.D. Von Hoff Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development J. Clin. Oncol. 17 1999 3631 3652
72. O.G. Scharovsky, V.R. Rozados, S.I. Gervasoni, and P. Matar Inhibition of Ras oncogene: a novel approach to antineoplastic therapy J. Biomed. Sci. 7 2000 292 298
73. G.E. Mark, and U.R. Rapp Primary structure of v-raf: relatedness to the src family of oncogenes Science 224 4646 1984 285 289
74. U.R. Rapp, M.D. Goldsborough, G.E. Mark, T.I. Bonner, J. Groffen, F.H. Reynolds Jr., and J.R. Stephenson Structure and biological activity of v-Raf, a unique oncogene transduced by a retrovirus Proc. Natl. Acad. Sci. U. S. A. 80 1983 4218 4222
75. H.W. Jansen, B. Ruckert, R. Lurz, and K. Bister Two unrelated cell-derived sequences in the genome of avian leukemia and carcinoma inducing retrovirus MH2 EMBO J. 2 1983 1969 1975
76. J. Avruch, X.F. Zhang, and J.M. Kyriakis Raf meets Ras: completing the framework of a signal transduction pathway Trends Biochem. Sci. 19 1994 279 283
77. C. Hagemann, and U.R. Rapp Isotype-specific functions of Raf kinases Exp. Cell Res. 253 1999 34 46
78. R. Schreck, and U.R. Rapp Raf kinases: oncogenesis and drug discovery Int. J. Cancer 119 2006 2261 2271
79. S.S. Sridhar, D. Hedley, and L.L. Siu Raf kinase as a target for anticancer therapeutics Mol. Cancer Ther. 4 2005 677 685
80. D. Strumberg, and S. Seeber Raf kinase inhibitors in oncology Onkologie 28 2005 101 107
81. N. Thompson, and J. Lyons Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery Curr. Opin. Pharmacol. 5 2005 350 356
82. C. Wellbrock, M. Karasarides, and R. Marais The RAF proteins take centre stage Nat. Rev. Mol. Cell Biol. 5 2004 875 885
83. M.J. Garnett, and R. Marais Guilty as charged: B-RAF is a human oncogene Cancer Cell 6 2004 313 319
84. H.G. Wang, U.R. Rapp, and J.C. Reed Bcl-2 targets the protein kinase Raf-1 to mitochondria Cell 87 1996 629 638
85. A. Nantel, M. Huber, and D.Y. Thomas Localization of endogenous Grb10 to the mitochondria and its interaction with the mitochondrial-associated Raf-1 pool J. Biol. Chem. 274 1999 35719 35724
86. A. Yuryev, M. Ono, S.A. Goff, F. Macaluso, and L.P. Wennogle Isoform specific localization of A-RAF in mitochondria Mol. Cell Biol. 20 2000 4870 4878
87. J. Zhu, V. Balan, A. Bronisz, K. Balan, H. Sun, D.T. Leicht, Z. Luo, J. Qin, J. Avruch, and G. Tzivion Identification of Raf-1 S471 as a novel phosphorylation site critical for Raf-1 and B-Raf kinase activities and for MEK binding Mol. Biol. Cell. 16 2005 4733 4744
88. P. Dent, T. Jelinek, D.K. Morrison, M.J. Weber, and T.W. Sturgill Reversal of Raf-1 activation by purified and membrane-associated protein phosphatases Science 268 1995 1902 1906
89. K.S. Saini, S. Loi, E. de Azambuja, O. Metzger-Filho, M.L. Saini, M. Ignatiadis, J.E. Dancey, and M.J. Piccart-Gebhart Targeting the PI3K/Akt/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer Cancer Treat. Rev. 39 2013 935 946
90. J. Polivka Jr., and F. Janku Molecular targets for cancer therapy in the PI3K/Akt/mTOR pathway Pharmacol. Ther. 142 2014 164 175
91. N. Bartalucci, P. Guglielmelli, and A.M. Vannucchi Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms, clinical lymphoma Myeloma & Leukemia 13 S2 2013 S307 S309
92. R. Dienstmann, J. Rodon, V. Serra, and J. Tabernero Picking the point of inhibition: a comparative review of PI3K/Akt/mTOR pathway inhibitors Mol. Cancer Ther. 13 5 2014 1021 1031
93. C. Porta, and R.A. Figlin Phosphatidylinositol-3-kinase/Akt signaling pathway and kidney cancer, and the therapeutic potential of phosphatidylinositol-3- kinase/Akt inhibitors J. Urol. 182 2009 2569 2577
94. A.M. Martelli, C. Evangelisti, F. Chiarini, C. Grimaldi, A. Cappellini, A. Ognibene, and J.A. McCubrey The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogenesis Biochimica Biophysica Acta 1803 2010 991 1002
95. R.D. Irons, and W.S. Stillman The process of leukemogenesis Environ. Health Perspect. 104 1996 1239 1246
96. K.T. Chan, K. Li, S.L. Liu, K.H. Chu, M. Toh, and W.D. Xie Cucurbitacin B inhibits STAT3 and the Raf/MEK/ERK pathway in leukemia cell line K562 Cancer Lett. 289 2010 46 52
97. A. Ng, G.M. Taylor, and O.B. Eden Secondary leukemia in a child with neuroblastoma while on oral etoposide: what is the cause? Pediatr. Hematol. Oncol. 17 3 2000 273 279
98. M. Yousefi, S.H. Ghaffari, A. Zekri, S. Ghanizadeh-Vesali, E. Hosseini, M. Rostami, S. Hassani, K. Alimoghaddam, and A. Ghavamzadeh Differential sensitivity of p44/p42-MAPK- and PI3K/Akt-targeted neuroblastoma subtypes to arsenic trioxide Neurochem. Int. 63 2013 809 817
99. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics CA Cancer J. Clin. 62 1 2012 10 29
100. H. Cheng, M. Shcherba, G. Pendurti, Y. Liang, B. Piperdi, and R. Perez-Soler Targeting the PI3K/Akt/mTOR pathway: potential for lung cancer treatment Lung Cancer Manag. 3 1 2014 67 75
101. S. Heavey, K.J. O'Byrne, and K. Gately Strategies for co-targeting the PI3K/Akt/mTOR pathway in NSCLC Cancer Treat. Rev. 40 2014 445 456
102. X. Chen, Q. Qin, W. Zhang, Y. Zhang, H. Zheng, C. Liu, Y. Yang, W. Xiong, and J. Yuan Activation of the PI3K/Akt/mTOR signaling pathway promotes DEHP induced Hep3B cell proliferation Food Chem. Toxicol. 59 2013 325 333
103. W. Yang, M. Shu, Y. Wang, R. Wang, Y. Hu, L. Meng, and Z. Lin 3D-QSAR and docking studies of 3-pyridine heterocyclic derivatives as potent PI3K/mTOR inhibitors J. Mole. Struct. 9 2013 49
104. E.A. Peterson, P.S. Andrews, X. Be, A.A. Boezio, T.L. Bush, A.C. Cheng, J.R. Coats, A.E. Colletti, K.W. Copeland, M. DuPont, R. Graceffa, B. Grubinska, J.C. Harmange, J.L. Kim, E.L. Mullady, P. Olivieri, L.B. Schenkel, M.K. Stanton, Y. Teffera, D.A. Whittington, T. Cai, and D.S. La Discovery of triazine-benzimidazoles as selective inhibitors of mTOR Bioorg. Med. Chem. Lett. 21 2011 2064 2070
105. S. Hong, S. Lee, B. Kim, H. Lee, S.S. Hong, and S. Hong Discovery of new azaindole-based PI3Ka inhibitors: apoptotic and antiangiogenic effect on cancer cells Bioorg. Med. Chem. Lett. 20 2010 7212 7215
106. S.T. Staben, T.P. Heffron, D.P. Sutherlin, S.R. Bhat, G.M. Castanedo, I.S. Chuckowree, J. Dotson, A.J. Folkes, L.S. Friedman, L. Lee, J. Lesnick, C. Lewis, J.M. Murray, J. Nonomiya, A.G. Olivero, E. Plise, J. Pang, W.W. Prior, L. Salphati, L. Rouge, D. Sampath, V. Tsui, N.C. Wan, S. Wang, C. Weismann, P. Wu, and B.Y. Zhu Structure-based optimization of pyrazolo-pyrimidine and -pyridine inhibitors of PI3K Bioorg. Med. Chem. Lett. 20 2010 6048 6051
107. S. Pecchi, P.A. Renhowe, C. Taylor, S. Kaufman, H. Merritt, M. Wiesmann, K.R. Shoemaker, M.S. Knapp, E. Ornelas, T.F. Hendrickson, W. Fantl, and C.F. Voliva Identification and structure-activity relationship of 2-morpholino 6-(3-hydroxyphenyl) pyrimidines, a class of potent and selective PI3 kinase inhibitors Bioorg. Med. Chem. Lett. 20 2010 6895 6898
108. S.T. Staben, M. Siu, R. Goldsmith, A.G. Olivero, S. Do, D.J. Burdick, T.P. Heffron, J. Dotson, D.P. Sutherlin, B.Y. Zhu, V. Tsui, H. Le, L. Lee, J. Lesnick, C. Lewis, J.M. Murray, J. Nonomiya, J. Pang, W.W. Prior, L. Salphati, L. Rouge, D. Sampath, S. Sideris, C. Wiesmann, and P. Wue Structure-based design of thienobenzoxepin inhibitors of PI3K Bioorg. Med. Chem. Lett. 21 2011 4054 4058
109. J.D. Kendall, P.D. O'Connor, A.J. Marshall, R. Frédérick, E.S. Marshall, C.L. Lill, W.J. Lee, S. Kolekar, M. Chao, A. Malik, S. Yu, C. Chaussade, C. Buchanan, G.W. Rewcastle, B.C. Baguley, J.U. Flanagan, S.M.F. Jamieson, W.A. Denny, and P.R. Shepherd Discovery of pyrazolo[1,5-a]pyridines as p110α-selective PI3 kinase inhibitors Bioorg. Med. Chem. 20 2012 69 85
110. A.M. Venkatesan, C.M. Dehnhardt, Z. Chen, E.D. Santos, O.D. Santos, M. Bursavich, A.M. Gilbert, J.W. Ellingboe, S. Ayral-Kaloustian, G. Khafizova, N. Brooijmans, R. Mallon, I. Hollander, L. Feldberg, J. Lucas, K. Yu, J. Gibbons, R. Abraham, and T.S. Mansour Novel imidazolopyrimidines as dual PI3K/mTOR inhibitors Bioorg. Med. Chem. Lett. 20 2010 653 656
111. M. Hayakawa, H. Kaizawa, H. Moritomo, T. Koizumi, T. Ohishi, M. Okada, M. Ohta, S.I. Tsukamoto, P. Parker, P. Workman, and M. Waterfield Synthesis and biological evaluation of 4-morpholino-2- phenylquinazolines and related derivatives as novel PI3 kinase p110a inhibitors Bioorg. Med. Chem. 14 2006 6847 6858
112. N. Ramnath, and A. Adjei Inhibitors of Raf kinase and MEK signaling Update Cancer Ther. 2 2007 111 118
113. Z. Suojun, W. Feng, G. Dongsheng, and L. Ting Targeting Raf/MEK/ERK pathway in pituitary adenomas Eur. J. Cancer 48 2012 389 395
114. A. Hematulin, D. Sagan, F. Eckardt-Schupp, and S. Moertl NBS1 is required for IGF-1 induced cellular proliferation through the Ras/Raf/MEK/ERK cascade Cell. Signal. 20 2008 2276 2285
115. A.T. Baines, D. Xu, and C.J. Der Inhibition of Ras for cancer treatment: the search continues Future Med. Chem. 3 14 2011 1787 1808
116. L. Gentry, A.A. Samatar, and C.J. Der Inhibitors of the ERK mitogen- activated protein kinase cascade for targeting Ras mutant cancers Enzymes 2013 67 106 34B
117. S. Hong, J. Kim, M. Lin, and J. Park The Raf/MEK/extracellular signal-regulated kinase 1/2 pathway can mediate growth inhibitory and differentiation signaling via androgen receptor downregulation in prostate cancer cells Exp. Cell Res. 317 2011 2671 2682
118. INK4a mRNA with advancing age in Acute Myeloid Leukemia Aging 1 11 2013 949 953
119. cip1 expression by growth factors and the extracellular matrix reveals a role for transient ERK activity in G1 Phase J. Cell Biol. 146 6 1999 1255 1264
120. S. Hong, J.H. Jeong, A.M. Chan, and J. Park Akt upregulates B-Raf Ser445 phosphorylation and ERK1/2 activation in prostate cancer cells in response to androgen depletion Exp. Cell Res. 319 2013 1732 1743
121. C. Neuzillet, A. Tijeras-Raballand, L. de Mestier, J. Cros, S. Faivre, and E. Raymond MEK in cancer and cancer therapy Pharmacol. Ther 141 2014 160 171
122. http://www.cancer.gov/cancertopics/research-updates/MEK (accessed 15.09.14).
123. B.K. Robbs, P.I. Lucena, and J.P.B. Viola The transcription factor NFAT1 induces apoptosis through cooperation with Ras/Raf/MEK/ERK pathway and upregulation of TNF-α expression Biochimica Biophysica Acta 1833 2013 2016 2028
124. J.P. Lai, D.S. Sandhu, C.D. Moser, S.C. Cazanave, A.M. Oseini, A.M. Shire, V. Shridhar, S.O. Sanderson, and L.R. Roberts Additive effect of apicidin and doxorubicin in sulfatase 1 expressing hepatocellular carcinoma in vitro and in vivo J. Hepatol. 50 2009 1112 1121
125. K.J. Schmitz, J. Wohlschlaeger, H. Lang, G.C. Sotiropoulos, M. Malago, and K. Steveling Activation of the ERK and Akt signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection J. Hepatol. 48 2008 83 90
126. S. Grant Cotargeting survival signaling pathways in cancer J. Clin. Invest. 118 2008 3003 3006
127. K. Takeishi, A. Taketomi, K. Shirabe, T. Toshima, T. Motomura, T. Ikegami, T. Yoshizumi, F. Sakane, and Y. Maehara Diacylglycerol kinase alpha enhances hepatocellular, carcinoma progression by activation of Ras-Raf-MEK-ERK pathway J. Hepato 57 2012 77 83
128. J. Kelly, R. Wolin, M. Connolly, A. Afonso, L. James, P. Kirshmeier, W.R. Bishop, and A.T. McPhail Synthesis of isomeric 3-piperidinyl and 3-pyrrolidinyl benzo[5,6]cyclohepta[1,2-b]pyridines: sulfonamido derivatives as inhibitors of Ras prenylation Bioorg. Med. Chem. 6 1998 673 686
129. A.K. Saha, L. Liu, R. Simoneaux, B. DeCorte, C. Meyer, S. Skrzat, H.J. Breslin, M.J. Kuklaa, and D.W. End Novel triazole based inhibitors of Ras farnesyl transferase Bioorg. Med. Chem. Lett. 15 2005 5407 5411
130. D. Berger, M. Dutia, D. Powell, B. Wu, A. Wissner, D.H. Boschelli, M.B. Floyd, N. Zhang, N. Torres, J. Levin, X. Du, D. Wojciechowicz, C. Discafani, C. Kohler, S.C. Kim, L.R. Feldberg, K. Collins, and R. Mallon Synthesis and evaluation of 4-anilino-6,7-dialkoxy-3- quinolinecarbonitriles as inhibitors of kinases of the Ras-MAPK signaling cascade Bioorg. Med. Chem. Lett. 13 2003 3031 3034
131. J.A. McCubrey, L.S. Steelman, S.L. Abrams, J.T. Lee, F. Chang, F.E. Bertrand, P.M. Navolanic, D.M. Terrian, R.A. Franklin, A.B. D'Assoro, J.L. Salisbury, M.C. Mazzarino, F. Stivala, and M. Libra Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt pathways in malignant transformation and drug resistance Advan. Enzyme Regul. 46 2006 249 279
132. J.A. McCubrey, L.S. Steelman, W.H. Chappell, S.L. Abrams, E.W.T. Wong, F. Chang, B. Lehmann, D.M. Terrian, M. Milella, A. Tafuri, F. Stivala, M. Libra, J. Basecke, C. Evangelisti, A.M. Martelli, and R.A. Franklin Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance Biochimica Biophysica Acta 1773 2007 1263 1284
133. W.H. Chappel, L.S. Steelman, J.M. Long, R.C. Kempf, S.L. Abrams, R.A. Franklin, J. Bäsecke, F. Stivala, M. Donia, P. Fagone, G. Malaponte, M.C. Mazzarino, F. Nicoletti, M. Libra, D. Maksimovic-Ivanic, S. Mijatovic, G. Montalto, M. Cervello, P. Laidler, M. Milella, A. Tafuri, A. Bonati, C. Evangelisti, L. Cocco, A.M. Martelli, and J.A. McCubrey Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health Oncotarget 2 2011 135 164
134. S. Yun, K.H. Jung, H. Lee, M.K. Son, J. Seo, H.H. Yan, B.H. Park, S. Hong, and S. Hong Synergistic anticancer activity of HS-173, a novel PI3K inhibitor in combination with Sorafenib against pancreatic cancer cells Cancer Lett. 331 2013 250 261
135. K.E. Sheppard, C. Cullinane, K.M. Hannan, M. Wall, J. Chan, F. Barber, J. Foo, D. Cameron, A. Neilsen, P. Ng, J. Ellul, M. Kleinschmidt, K.M. Kinross, D.D. Bowtell, J.G. Christensen, R.J. Hicks, R.W. Johnstone, G.A. McArthur, R.D. Hannan, W.A. Phillips, and R.B. Pearson Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors Eur. J. Cancer 49 2013 3936 3944
136. Q. Li, J. Wua, H. Zheng, K. Liu, T.L. Guo, Y. Liu, S.T. Eblen, S. Grant, and S. Zhang Discovery of 3-(2-aminoethyl)-5-(3-phenyl-propylidene)-thiazolidine-2,4-dione as a dual inhibitor of the Raf/MEK/ERK and the PI3K/Akt signaling pathways Bioorg. Med. Chem. Lett. 20 2010 4526 4530
137. S. Wang, Y.C. Yoon, M. Sung, J. Hwang, H. Hur, H. Kim, H.J. Yang, M. Kim, D.Y. Kwon, and J. Park Citrus-derived auraptene stimulates angiogenesis by activating the Erk- and PI3K/Akt/eNOS-dependent signaling pathways in human umbilical vein endothelial cells J. Funct. Foods 4 2012 899 905
138. G. Polier, J. Neumann, F. Thuaud, N. Ribeiro, C. Gelhaus, H. Schmidt, M. Giaisi, R. Kohler, W.W. Muller, P. Proksch, M. Leippe, O. Janssen, L. de saubry, P.H. Krammer, and M. Li-Weber The natural anticancer compounds rocaglamides inhibit the Raf-MEK-ERK pathway by targeting prohibitin 1 and 2 Chem. Biol. 19 9 2012 1093 1104
139. C. Tang, and C. Tsai CCL2 increases MMP-9 expression and cell motility in human chondrosarcoma cells via the Ras/Raf/MEK/ERK/NF-kB signaling pathway Biochem. Pharmacol. 83 2012 335 344
140. B. Roy, A.K. Pattanaik, J. Das, S.K. Bhutia, B. Behera, P. Singh, and T.K. Maiti Role of PI3K/Akt/mTOR and MEK/ERK pathway in Concanavalin A induced autophagy in HeLa cells Chem. Biol. Interact. 210 2014 96 102
141. P.B. Chapman Improved survival with vemurafenib in melanoma with BRaf V600E mutation N. Engl. J. Med. 364 2011 2507 2516
142. K.T. Flaherty Improved survival with MEK inhibition in BRaf-mutated melanoma N. Engl. J. Med. 367 2012 107 114
143. M.S. Carlino, J.R. Todd, K. Gowrishankar, B. Mijatov, G.M. Pupo, C. Fung, S. Snoyman, P. Hersey, G.V. Long, R.F. Kefford, and H. Rizos Differential activity of MEK and ERK inhibitors in BRaf inhibitor resistant melanoma Mol. Oncol. 8 2014 544 554
144. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 2011 646 674
145. I. Sánchez-Hernández, P. Baquero, L. Calleros, and A. Chiloeches Dual inhibition of V600EBRAF and the PI3K/Akt/mTOR pathway cooperates to induce apoptosis in melanoma cells through a MEK-independent mechanism Cancer Lett. 314 2012 244 255
146. E. Kandil, K. Tsumagari, J. Ma, Z.Y. Abd Elmageed, X. Li, D. Slakey, D. Mondal, and A.B. Abdel-Mageed Synergistic inhibition of thyroid cancer by suppressing MAPK/PI3K/Akt pathways J. Surg. Res. 184 2013 898 906
147. K. Kavitha, J. Kowshik, T.K.K. Kishore, A.B. Baba, and S. Nagini Astaxanthin inhibits NF-κB and Wnt/β-catenin signaling pathways via inactivation of Erk/MAPK and PI3K/Akt to induce intrinsic apoptosis in a hamster model of oral cancer Biochim. Biophys. Acta 1830 2013 4433 4444
148. J. Li, G. Wang, C. Wang, Y. Zhao, H. Zhang, Z. Tan, Z. Song, M. Ding, and H. Deng MEK/ERK signaling contributes to the maintenance of human embryonic stem cell self-renewal Differentiation 75 2007 299 307
149. Q. Luo, Y. Gu, W. Zheng, X. Wu, F. Gong, L. Gu, Y. Sun, and Q. Xu Erlotinib inhibits T-cell-mediated immune response via down-regulation of the C-Raf/ERK cascade and Akt signaling pathway Toxicol. Appl. Pharmacol. 251 2011 130 136
150. J. Jakubíkova, J. Sedlák, R. Mithen, and Y. Bao Role of PI3K/Akt and MEK/ERK signaling pathways in sulforaphane- and erucin-induced phase II enzymes and MRP2 transcription, G2/M arrest and cell death in Caco-2 cells Biochem. Pharmacol. 69 2005 1543 1552
151. A.M. Martelli, G. Tabellini, F. Ricci, C. Evangelisti, F. Chiarini, R. Bortul, J.A. McCubrey, and F.A. Manzoli PI3K/Akt/mTORC1 and MEK/ERK signaling in T-cell acute lymphoblastic leukemia: New options for targeted therapy Adv. Enzyme Regul. 52 2012 214 227
152. M.J. Sambade, J.T. Camp, R.J. Kimple, C.I. Sartor, and J.M. Shields Mechanism of lapatinib-mediated radiosensitization of breast cancer cells is primarily by inhibition of the Raf > MEK > ERK mitogen-activated proteinv kinase cascade and radiosensitization of lapatinib-resistant cells restored by direct inhibition of MEK Radiother. Oncol. 93 2009 639 644
153. E. Aksamitiene, B.N. Kholodenko, W. Kolch, J.B. Hoek, and A. Kiyatkin PI3K/Akt-sensitive MEK-independent compensatory circuit of ERK activation in ER-positive PI3K-mutant T47D breast cancer cells Cell. Signal. 22 2010 1369 1378
154. L. Yang, W. Guo, Q. Zhang, H. Li, X. Liu, Y. Yang, J. Zuo, and W. Liu Crosstalk between Raf/MEK/ERK and PI3K/Akt in suppression of Bax conformational change by Grp75 under glucose deprivation conditions J. Mol. Biol. 414 2011 654 666
155. A. Lorenzini, M. Tresini, M. Mawal-Dewan, L. Frisonia, H. Zhanga, R.G. Allena, C. Sella, and V.J. Cristofalo Role of the Raf/MEK/ERK and the PI3K/Akt(PKB) pathways in fibroblast senescence Exp. Gerontol. 37 2002 1149 1156
156. K. Liu, W. Rao, H. Parikh, Q. Li, T.L. Guo, S. Grant, G.E. Kellogg, and S. Zhang 3,5-Disubstituted-thiazolidine-2,4-dione analogs as anticancer agents: design, synthesis and biological characterization Eur. J. Med. Chem. 47 2012 125 137